Phase 3 ADorable-1 trial results show lebrikizumab-libkz provides skin clearance and itch relief in children with moderate to severe atopic dermatitis.

In phase 3 clinical trials, tildrakizumab treatment was associated with significantly higher ACR20 response rates at week 24 compared with placebo.

Bezuclastinib is an oral, selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation, a primary driver of systemic mastocytosis.

All-cause mortality significantly lower with GLP-1 RA use, with consistent benefit across major cancer types, most GLP-1 RA types.

Findings from the FIND-CKD trial indicate finerenone may provide a new treatment option for slowing renal function loss in CKD patients without diabetes.

With permission, the tool can review information such as test results, medical history, and medications. HealthDay News — Microsoft is rolling out a new artificial intelligence (AI) tool designed to ...

HealthDay News — For children aged 2 to 5 years with atopic dermatitis (AD), roflumilast cream 0.05% has a favorable long-term safety profile and efficacy for up to 56 weeks, according to a study ...

HealthDay News — Digital media use is consistently associated with risks to child and adolescent mental health and development globally, according to a review published online March 9 in JAMA ...

Medical debt associated with increase in probability of deferred dental care, medical care, mental health care ...

Courts may deny motions for judgment notwithstanding the verdict when a jury reaches a reasonable decision based on evidence of a patient's failure to follow a prescribed treatment plan.

Adults aged 18 to 49 years at increased risk for RSV-associated lower respiratory tract disease are now eligible for the Arexvy vaccine.

A phase 3 study of eftilagimod alfa for NSCLC is ending early due to futility, according to an update from developer Immutep.